Article

BREAKING: Deal Near on SGR Fix

The joint House-Senate conference committee tasked with fixing the Medicare SGR formula is nearing a deal, according to news sources.

The $20-billion fix, which would avoid a 28% cut in physician payments scheduled to begin March 1, would reportedly be offset by cuts in the budget.

Source: MedPage Today

Related Videos
Roberto Salgado, MD.
1 KOL is featured in this series.
1 expert is featured in this series.
5 experts are featured in this series
Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson chair in preventative cardiology, Tulane University School of Medicine
Related Content
lab test tubes | Image credit: kwanchaift – stock.adobe.com
December 22nd 2024

Study Highlights Trends, Emerging Innovations in DMD Research

Hayden E. Klein
An analysis revealed global trends and emerging focus areas in Duchenne muscular dystrophy (DMD) research, emphasizing the growing impact of precision medicine and gene therapies.
Managed Care Cast
December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi
Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Center on Health Equity and Access
December 21st 2024

Health Equity & Access Weekly Roundup: December 21, 2024

Giuliana Grossi
The Center on Health Equity & Access provides news and expert insights on research, health policy, and the impact of social determinants on health.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
FDA website | Image credit: Postmodern Studio – stock.adobe.com
December 20th 2024

FDA Rejects Sotagliflozin for Type 1 Diabetes; Lexicon Shifts Focus

Hayden E. Klein
The FDA issued a complete response letter for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control.
FDA approved with health icons and a doctor | Image credit: wladimir1804 - stock.adobe.com
December 20th 2024

Weight Loss Drug Tirzepatide Now Approved for Sleep Apnea in Adults With Obesity

Laura Joszt, MA
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo